Insider Selling: Humacyte, Inc. (NASDAQ:HUMA) Director Sells 427,459 Shares of Stock

Humacyte, Inc. (NASDAQ:HUMA) Director Brady W. Dougan sold 427,459 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Humacyte Trading Down 0.2 %

Shares of HUMA traded down $0.01 during midday trading on Wednesday, reaching $4.41. The company had a trading volume of 2,094,875 shares, compared to its average volume of 2,412,612. The firm has a 50 day simple moving average of $5.38 and a 200-day simple moving average of $6.20. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. The stock has a market cap of $555.04 million, a PE ratio of -3.29 and a beta of 1.47. Humacyte, Inc. has a 1-year low of $2.43 and a 1-year high of $9.97.

Analyst Upgrades and Downgrades

HUMA has been the subject of a number of recent research reports. Benchmark reiterated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research note on Thursday, October 10th. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Humacyte in a report on Wednesday, November 13th. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price target on shares of Humacyte in a report on Friday, September 20th. Finally, BTIG Research reiterated a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $11.00.

Institutional Investors Weigh In On Humacyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HUMA. nVerses Capital LLC acquired a new position in shares of Humacyte in the 2nd quarter worth approximately $28,000. Concurrent Investment Advisors LLC acquired a new stake in Humacyte in the third quarter valued at approximately $75,000. Principal Financial Group Inc. acquired a new position in Humacyte during the 2nd quarter worth approximately $83,000. FORA Capital LLC acquired a new stake in Humacyte in the third quarter valued at $96,000. Finally, Profund Advisors LLC purchased a new stake in Humacyte during the 2nd quarter worth about $97,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.